Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy

•VEGFR-2 is aberrantly expressed in many malignant tumors.•Developments or discoveries of VEGFR-2-based inhibitors with multi-targeting capabilities were summarized.•The rational design and SARs of multi-targeting agents were discussed.•The therapeutic effects might be improved by simultaneously inhibiting VEGFR-2 and other targets.